Cargando…
COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India
BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829103/ https://www.ncbi.nlm.nih.gov/pubmed/35155822 http://dx.doi.org/10.1002/jgh3.12686 |
_version_ | 1784647995934900224 |
---|---|
author | Kale, Aditya Shinde, Leela Sundaram, Sridhar Patra, Biswa R Rao, Praveen K Irtaza, Mohd Shukla, Akash |
author_facet | Kale, Aditya Shinde, Leela Sundaram, Sridhar Patra, Biswa R Rao, Praveen K Irtaza, Mohd Shukla, Akash |
author_sort | Kale, Aditya |
collection | PubMed |
description | BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out of 350, 302 participated in the survey. Demographic data, disease severity at the time of survey, extent of disease, details of therapy, and adherence were noted. A validated questionnaire addressing information source, perception of COVID‐19 situation, contact with healthcare, and adherence to standard precautions was administered telephonically. RESULTS: Out of 350 contacted patients, 302 (86.28%) patients participated in the survey. Median age of cohort was 39 years. Ulcerative colitis (UC) constituted 79%, 16% Crohn's disease (CD), and 5% IBD‐unclassified. At the time of survey, 86.98% patients with UC were in clinical remission and 75.75% of CD patients were generally well. A total of 115 (38%) cases were nonadherent to therapy due to unavailability of medicines (66.38%), financial constraints (25.21%) and inability to reach healthcare facility (3.6%). Disease flare was seen in 14.2% and correlated well with nonadherence. Existing drug therapy was switched to alternative drug in 70 (23.17%) cases due to unavailability (74%). Social media (52.3%) and television (40.4%) were the common sources of information about the pandemic. Telemedicine platforms (WhatsApp and telephone) were used by 180 (59.6%) patients for consultation with good acceptance (81.6%). 87 (28.8%) patients failed to contact healthcare. Apprehension regarding severe COVID infection was noted in 80% while 29% thought that IBD therapy could increase infection risk. Adherence to wearing mask, hand washing, and social distancing was 100%. CONCLUSION: Pandemic resulted in disruption of healthcare visits and medication supply. Majority were concerned about increased risk of COVID‐19 infection and adhered to standard precautions. Mobile phone‐based formats for patient care may be an alternative due to patient acceptance and convenience. |
format | Online Article Text |
id | pubmed-8829103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-88291032022-02-11 COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India Kale, Aditya Shinde, Leela Sundaram, Sridhar Patra, Biswa R Rao, Praveen K Irtaza, Mohd Shukla, Akash JGH Open Original Articles BACKGROUND AND AIM: The COVID pandemic and countrywide lockdown has had significant impact on patients with inflammatory bowel disease (IBD), with delay in diagnosis, difficulty in access to healthcare and unavailability of drugs. We conducted a telephonic survey to assess this impact. METHODS: Out of 350, 302 participated in the survey. Demographic data, disease severity at the time of survey, extent of disease, details of therapy, and adherence were noted. A validated questionnaire addressing information source, perception of COVID‐19 situation, contact with healthcare, and adherence to standard precautions was administered telephonically. RESULTS: Out of 350 contacted patients, 302 (86.28%) patients participated in the survey. Median age of cohort was 39 years. Ulcerative colitis (UC) constituted 79%, 16% Crohn's disease (CD), and 5% IBD‐unclassified. At the time of survey, 86.98% patients with UC were in clinical remission and 75.75% of CD patients were generally well. A total of 115 (38%) cases were nonadherent to therapy due to unavailability of medicines (66.38%), financial constraints (25.21%) and inability to reach healthcare facility (3.6%). Disease flare was seen in 14.2% and correlated well with nonadherence. Existing drug therapy was switched to alternative drug in 70 (23.17%) cases due to unavailability (74%). Social media (52.3%) and television (40.4%) were the common sources of information about the pandemic. Telemedicine platforms (WhatsApp and telephone) were used by 180 (59.6%) patients for consultation with good acceptance (81.6%). 87 (28.8%) patients failed to contact healthcare. Apprehension regarding severe COVID infection was noted in 80% while 29% thought that IBD therapy could increase infection risk. Adherence to wearing mask, hand washing, and social distancing was 100%. CONCLUSION: Pandemic resulted in disruption of healthcare visits and medication supply. Majority were concerned about increased risk of COVID‐19 infection and adhered to standard precautions. Mobile phone‐based formats for patient care may be an alternative due to patient acceptance and convenience. Wiley Publishing Asia Pty Ltd 2022-01-15 /pmc/articles/PMC8829103/ /pubmed/35155822 http://dx.doi.org/10.1002/jgh3.12686 Text en © 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Kale, Aditya Shinde, Leela Sundaram, Sridhar Patra, Biswa R Rao, Praveen K Irtaza, Mohd Shukla, Akash COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title | COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title_full | COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title_fullStr | COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title_full_unstemmed | COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title_short | COVID‐19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in India |
title_sort | covid‐19 pandemic and inflammatory bowel disease from patients' perspective: a survey from covid epicenter in india |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829103/ https://www.ncbi.nlm.nih.gov/pubmed/35155822 http://dx.doi.org/10.1002/jgh3.12686 |
work_keys_str_mv | AT kaleaditya covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT shindeleela covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT sundaramsridhar covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT patrabiswar covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT raopraveenk covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT irtazamohd covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia AT shuklaakash covid19pandemicandinflammatoryboweldiseasefrompatientsperspectiveasurveyfromcovidepicenterinindia |